Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1

(MedPage Today) -- Intratumoral injection of an investigational agent, BO-112, combined with pembrolizumab (Keytruda) demonstrated promising efficacy in certain patients with advanced melanoma refractory to anti-PD-1-based therapy, according to...